Coniine is an optically active toxic piperidine alkaloid and nicotinic acetylcholine receptor (nAChR) agonist found in poison hemlock (Conium maculatum L.). Coniine teratogenicity is hypothesized to be due to the binding, activation, and prolonged desensitization of fetal muscletype nAChR, which results in the complete inhibition of fetal movement. However, pharmacological evidence of coniine actions at fetal-muscle type nAChR is lacking. The present study compared (-)-coniine, (+)-coniine and nicotine for the ability to inhibit fetal movement in a day 40 pregnant goat model and in TE-671 cells which express fetal muscle-type nAChR.
Introduction
Coniine is an optically active piperidine alkaloid and nicotinic acetylcholine receptor (nAChR) agonist found in poison hemlock (Conium maculatum L.) and introduced from Europe (Marion et al., 1950; Lopez et al., 1999; Vetter, 2004; Lee et al., 2008) (Figure 1 ). Acute poisonings by poison hemlock are well documented in both humans and animals (Frank et al., 1995; West et al., 2009; Swerczek 2012) . Livestock typically consume poison hemlock plant material or seed, in contaminated feed or forages, and the alkaloids readily cross the placenta and their developing fetuses are exposed to coniine as a result (Edmonds et al., 1972; Panter et al., 1985b; Schep et al., 2009) . If animals survive the initial exposure to poison hemlock, they may develop a preference for the plant and pigs in particular develop an appetite for poison hemlock (Kingsbury 5 J P E T # 1 9 9 5 8 8
The acute effects of coniine are due to its ability to activate and then desensitize nAChRs from the persistent action of the alkaloid at the receptor. This leads to receptor desensitization, and inhibition of cation conductances (Buccafusco, 2004) . The MCC teratogenic actions of coniine are at fetal muscle-type nAChRs, which are ligand-gated cation channels expressed by the developing fetus. These nAChR have a subunit composition of (α 1 ) 2 β 1 γ δ , with ligandbinding sites at the α δ and α γ subunits interfaces, and activated by the binding of two molecules of acetylcholine. Studies using coniine and other nAChR agonists such as the pyridine alkaloid nicotine ( Figure 1 ) suggest that teratogenesis results from the binding, activation, and inhibition of these receptors (Green et al., 2012) .
The teratogenicity of coniine was first documented at this laboratory by Keeler (1974) .
Dosing of 3.3 mg/kg coniine to pregnant cattle from days 55 to 70 of gestation resulted in the formation of terata in the offspring. Sheep required daily doses of 44 mg/kg coniine between 12
to 65 days of gestation to produce terata (Keeler et al., 1980) . Later work at this laboratory by 6 J P E T # 1 9 9 5 8 8 coniine enantiomer is more potent. There have been no recent reports of the i.v. dosing of purified coniine compounds to a large animal such as a goat, nor the effects of i.v. dosing of purified coniine enantiomers on fetal movement in livestock or reports of the competitive antagonism of coniine actions by conotoxins.
We hypothesized that (-)-coniine would be more effective than (+)-coniine at inhibiting fetal movement in a day 40 pregnant goat model, and that the actions of (+)-and (-) coniine can be antagonized by alpha conotoxin (CTx) EI and GI in TE-671 cells. Over the course of testing the hypothesis, we sought to demonstrate stereoselectivity, agonist specificity, concentrationdependency and antagonism of coniine actions using TE-671 cells and a goat model. needed to produce clinical signs of intoxication including salivation, urination, defecation and muscle fasciculations followed by collapse onto their sternum (data not shown), this dose was then used in the day 40 pregnant goat study.
Coniine mandelate crystallization procedure.
(±)-Coniine (502.6 mg, 3.95 mmol) and (-)-mandelic acid (605.5 mg, 3.98 mmol) were added to a 16 ml screw top glass test tube. To the (±)-coniine and (-)-mandelic acid mixture was added 1.6 ml methanol and the mixture warmed until all (±)-coniine and (-)-mandelic acid was dissolved, then anhydrous diethyl ether (4.00 ml) (Fisher Scientific, Fair Lawn, NJ) was added and the mixture put on ice. Crystals of (+)-coniine (-)-mandelate began to form within 30 min.
of adding the diethyl ether. After 16 hr at -20 ˚C the solvent was filtered from the crystals, the crystals collected, and dried in vacuo. The crystals were recrystallized (3X) by dissolving the crystals in methanol (1.6 mL), adding diethyl ether (4mL), and then allowing them to crystallize at -20 ˚C. et al., 1981; Groebe et al., 1995) . We also used CTx EI obtained from
American Peptide Company, classified as an α 4/7-CTx isolated from C. ermineus that targets both mammalian α δ and α γ subunit interface ligand-binding sites with nearly equal affinity (Martinez et al., 1995; Azam and McIntosh, 2009) 
Procedures.
The human rhabdomyosarcoma cell line TE-671 was obtained from ATCC. Membrane depolarization responses from the addition of nAChR agonists were measured by changes in fluorescence of a membrane potential-sensitive dye as previously described (Green et al., 2010) .
A brief summary of the method follows: TE-671 cells in 96 well black walled cell culture plates were equilibrated to room temperature for 10 minutes, and then loaded with dye for 30 minutes. 
In all experiments, ten duplicate wells of a dilution series of epibatidine was included, and each experiment was visually inspected for a stable baseline for the data from that 96 well plate to be included in analysis of individual compound responses. The depolarizing responses to the coniine enantiomers, acetylcholine, and nicotine were normalized to the maximum responses generated by (±)-epibatidine.
Data analysis.
Nonlinear regression models (sigmoidal dose-response (variable slope) and sigmoidal dose- The effects of CTx EI and GI on actions ACh in TE-671 cells were examined next ( Figure 5 , Table 3 ). ACh was a full agonist with a maximum response of 96 ± 2 % of epibatidine. Thirty minute pretreatment with 1μM CTx EI shifted the ACh concentration-effect curve to the right and increased the maximum response of TE-671 cells to ACh by 25%. Although 1μM CTx GI did not shift the ACh concentration-effect curve to the right, the maximum response of TE-671 cells to ACh was increased by 11%. The three concentration-effect curves were compared by F-
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Concentration-dependent effects of CTx EI and GI on the actions of (+)-and (-)-coniine
test and there were significant differences between them (P = 0.0014, F-test). The data were analyzed by two-way ANOVA and there was a significant interaction between drug treatment and concentration (P = 0.02, two-way ANOVA). When the datum points were examined by a
Bonferroni multiple comparisons post-test, 1 μ M ACh in the presence of 1 μ M CTx EI was significantly different from control (P < 0.05, two-way ANOVA, Bonferroni multiple comparison test).
Effects of 1.0 μ M CTx EI and GI on the actions of coniine mandelic acid combinations in TE-671 cells.
The next series of experiments documented the potencies and efficacies of the coniine mandelic acid combinations in TE-671 cells ( Figure 6 ; Table 4 When either of the free mandelic acid enantiomers were included with serial dilutions of (±)-coniine, CTx EI did not block the (±)-coniine induced change in membrane potential sensing dye
fluorescence. In the absence of coniine, the mandelic acid enantiomers and CTx EI were also without effect except at a 1 mM concentration of (+)-mandelic acid. Interestingly, CTx GI blocked all concentrations (±)-coniine in such a manner that the software package was unable to determine a best-fit line. The EC 50 values for the coniine racemate in the absence and presence of the CTxs are displayed in Table 3 
(+)-Coniine (-)-mandelic acid and (-)-coniine (+)-mandelic acid actions in a day 40 pregnant goat model.
After completing the series of TE-671 cell experiments, the coniine mandelic acid enantiomers were tested in the day 40 pregnant goat model. In this experiment (+)-coniine (-)-mandelic acid and (-)-coniine (+)-mandelic acid compounds were crystallized from racemic liquid coniine purchased from Sigma Chemical company as described in the materials and methods section.
The enantiomers were not converted to the hydrochloride salt that we used in previous experiments due to the loss of coniine (low yield) when converting coniine mandalate to coniine HCl.
When day 40 pregnant does were dosed with 8.0 mg/kg of either (+)-or (-)-coniine, mandelic acid, there were immediate signs of cholinergic toxicity which included salivation, In a separate series of experiments, as a piperidine to pyridine alkaloid structural control we tested the actions of nicotine in both TE-671 cells and the day 40 pregnant goat model. A representative tracing of the raw data for a nicotine response is displayed in Figure 2 . In the TE-671 cell experiments, the nicotine concentration-effect curves were shifted to the right in the
presence of CTx EI or GI and the three curves were significantly different as determined by Ftest (P < 0.0001, F-test) ( Figure 9A ). CTx GI decreased the maximum response of 1 mM nicotine by 69 percent compared to control (Table 3) . When the data were analyzed by two-way ANOVA, there was significant variation between drug treatment and concentration (P = 0.004, P < 0.0001; for treatment and concentration respectively, two-way ANOVA). The 100 μ M and 1 mM nicotine concentrations in the presence of 1 μ M CTx GI were significantly different from their respective nicotine control values (P < 0.001, P < 0.01 for nicotine concentrations of 100 μ M, and 1 mM, respectively, two-way ANOVA, Bonferroni multiple comparison test).
In the day 40 pregnant goat model, nicotine at an i.v. dose of 0.6 mg/kg caused immediate clinical signs of cholinergic toxicity in the does although they recovered similarly to those dosed with coniine. When the ultrasound fetal movement data were analyzed, there were no significant differences detected (P > 0.05, ANOVA, nicotine verses saline for each timepoint)
between the saline controls and the nicotine-treated fetuses (Figure 9b ).
Discussion
Numerous reports have described the teratogenicity of coniine (Green et al., 2012) . However, they typically used orally dosed poison hemlock plant material or included experiments that did not monitor the effects of coniine on fetal movement (e.g., Keeler and Balls, 1978; Panter et al., 1990a, b) . In a chick model, Forsyth et al. (1996) documented that nicotine and coniine can cause deformities and inhibit movement but they were unable to block coniine actions with nAChR antagonists and thereby unable to conclude nAChR mediated effects of the agonists.
This research attempts to overcome these shortcomings by providing pharmacological evidence for coniine actions at fetal muscle-type nAChR. We used TE-671 cells, a human rhabdomyosarcoma cell line which expresses fetal muscle-type nAChR for in vitro experiments.
Secondly, we used a fetal goat movement model for in vivo radio-ultrasound experiments to measure the inhibition of fetal movement, the putative mechanism behind MCC-type defect formation.
In TE-671 cells, the effects of coniine were concentration-dependent ( Figures 3, 4 , 6) and were antagonized by both CTxs. The results from the first cell-based experiments did not have the expected order of potency for the coniine HCl enantiomers as observed in previous work (Lee et al., 2008; Green et al., 2010) . This result could have been due to the sequential nature of the experiments where concentration-effect curves for each enantiomer were tested in the presence and absence of both CTxs separately over an extended period. Later experiments with the coniine mandelic acid combinations during the same two-week period had the expected order of potency in TE-671 cells of (-)-coniine (+)-mandelic acid > (+)-coniine (-) mandelic acid. We also confirmed the coniine stereoselective inhibition of fetal movement in goats hypothesis. These observations confirm our hypothesis that (-)-coniine would be more effective than (+)-coniine at inhibiting fetal movement in a day 40 pregnant goat model, and that the actions of coniine can be antagonized by CTxs in TE-671 cells to provide pharmacological evidence for coniine actions at fetal muscle-type nAChR.
Next, we compared the actions of coniine, a piperidine alkaloid to nicotine, a pyridine alkaloid in cell culture and goats. There are reports of sows that consumed waste stalks of tobacco produced deformed piglets and the teratogen was assumed to be nicotine (Crowe, 1969; Menges et al., 1970; Crowe and Pike, 1973; Crowe and Swerczek, 1974) . However, when nicotine was dosed to pregnant sows as an isolated alkaloid it did not produce MCC deformities in the sow's piglets so the deformities were attributed to anabasine which is found at high concentrations the pith of tobacco stalks (Crow, 1978; Keeler, 1979) .
In this work, nicotine like coniine acted as an agonist in TE-671 cells ( Figure 9A ) and its actions were antagonized by 1 μ M CTx GI. CTx GI has a 10,000 fold greater affinity for the α δ ligand-binding site of the fetal muscle-type nAChR than the α γ ligand-binding site (Azam and Mcintosh, 2009 ). This result suggests that nicotine has a preference for the α δ site in this model system. Conversely, the actions of coniine were sensitive to both CTxs although there was a complete block of coniine actions by 1 μ M CTx GI (Figure 4 ) suggesting a slight preference for the α δ site. In the day 40 pregnant goat model, nicotine was without significant effect on fetal movement. These results suggest that although both alkaloids are agonists at fetal muscle-type nAChR, there are agonist-specific differences in their interactions with the receptor in vivo and This article has not been copyedited and formatted. The final version may differ from this version.
in vitro. Moreover, the inhibition of fetal movement and thus teratogenicity is restricted to the piperidine alkaloid coniine which has the required structural features for teratogenicity (Keeler and Balls, 1978) . This observation provides evidence for agonist specific inhibition of fetal movement by piperidine alkaloids at fetal muscle-type nAChR.
In this work, we used two CTxs from different subfamilies to control for any differences in agonist-antagonist interactions at the ligand-binding site. In previous studies with TE-671 cells we have documented agonist-specific effects with methyllycaconitine (MLA) a nAChR selective antagonist (Green et al., 2011) . In this work, each of the test agonists were antagonized by one or both CTxs suggesting that there are differential agonist-antagonist specific interactions at this receptor. Interestingly, CTxs at low concentrations (typically 1 and 10 nM) potentiated the responses of TE-671 cells to coniine HCl (Figures 3, 4) . , 2000; Lopez-Vera, et al., 2007) . An alternative explanation of these results is that there was the formation of a "hemi-equilibrium" state between the CTxs, and, nicotine and coniine, but not ACh. The formation of a "hemiequilibrium" state due to slow dissociation of the antagonist from the receptor and incomplete reequilibration after agonist addition would decrease the maxima of concentration-effect curves (Kenakin, 2009) . CTxs are known to have slow dissociations rates from nAChR ligand-binding sites (Prince and Sine, 1999) . We therefore speculate that these differences in antagonism between ACh and the other agonists are twofold. First, there may be specific differences in the ligand-binding site agonist-antagonist interactions that could affect the rate of offset of the antagonist from the receptor during re-equilibration after agonist addition. Secondly, the short time-span of the membrane potential sensing dye response could preclude the ability of the system to re-equilibrate after the addition of coniine or nicotine in the presence of the CTxs.
In this study, coniine mandelic acid compounds were tested in both TE-671 cells and goats. In TE-671 cells, the presence of mandelic acid prevented the antagonism of the coniine response by CTx EI but not GI ( Figure 6 ). To confirm this observation, we ran a separate series of concentration-effect experiments with mixtures of (±)-coniine (the starting material for the isolation of the enantiomers from Sigma-Aldrich) and the mandelic acids in the presence of CTx EI ( Figure 7 ). In these experiments, (±)-coniine alone was antagonized by CTx EI and GI.
However, in the presence of mandelic acid, CTx EI was without effect. The lack of CTx EI antagonism could have been due to mandelic acid interactions with the receptor or the alkaloid itself. The exact mechanism of mandelic acid inhibition of CTx nAChR antagonism is beyond Over the course of testing our hypothesis that the teratogenicity of piperidine alkaloids is due to their actions at fetal muscle-type nAChR we used both in vitro and in vivo models. In this work as in previous reports, we have documented the concentration-dependency of coniine enantiomers in TE-671 cells (Lee et al., 2008; Green et al., 2010) . We demonstrated the stereoselectivity of fetal muscle-type nAChR for (-)-coniine (+)-mandelic acid in TE-671 cells and in the goat model. Agonist specificity was documented by the inhibition of fetal movement by coniine a piperidine alkaloid, but not by nicotine a pyridine alkaloid. These differences were most likely due to structure-activity relationships between the ligand and the receptor as these alkaloids readily cross the placenta (Schep et al., 2009) . Finally, we compared the actions of the coniine HCl enantiomers and the coniine mandelic acid combinations in the presence and absence of two CTxs both of which are potent and selective muscle-type nAChR antagonists. In TE-671 cells at a concentration of 1 μ M both CTxs antagonized the actions of coniine. Taken together these results provide evidence that the piperidine alkaloid coniine is acting at fetal muscle-type nAChR to inhibit fetal movement.
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